Possible billion-euro deal: Novo Nordisk wants to acquire MHH spin-off

26-Mar-2024 - Cardior Pharmaceuticals is developing a drug for the treatment of heart failure. The Danish pharmaceutical group Novo Nordisk is planning to acquire the start-up, which was founded in 2016, for a potential price of 1.025 billion euros. Cardiovascular diseases are the most common cause of death ...

Cardior Raises EUR 64 Million to Develop RNA Therapeutics Against Cardiac Disease

Start-up pursues a unique approach for the treatment

27-Aug-2021 - Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMed Partners, ...

Cardior Pharmaceuticals raises €15 million in series A financing

Starting to develop first-in-class ncRNA therapeutics and diagnostics for heart related diseases

11-May-2017 - Cardior Pharmaceuticals, a spin-off from Hannover Medical School (MHH), today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III ...